Business
Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States
TSX Venture: QPT EDMONTON, June 14, 2012 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) (...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\n\n\nTSX Venture: QPT\n\n\nEDMONTON, June 14, 2012 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT)\n (\"Quest\" or the \"Company\"), a pharmaceutical company developing and\n commercializing products for the treatment of cancer, announces that it\n has received clearance from the United States Food and Drug\n Administration to initiate U.S. sites for an ongoing international\n Phase II clinical trial for oregovomab in advanced ovarian cancer\n patients. The objective of this study is to evaluate whether optimally\n dosed oregovomab in conjunction with front-line chemotherapy will\n generate the same or an improved immune and clinical response, as seen\n in a previous Phase II clinical trial in a similar ovarian cancer\n patient population.\n\n\nThe U.S. centers include Michiana Hematology and Oncology at South Bend,\n Indiana with Dr. Michael Method as the lead investigator; University of Connecticut Health Center at Farmington, Connecticut with\n Dr. Molly R. Brewer as the lead investigator, and the Stanford Cancer\n Institute at Stanford, California with Dr. Jonathan S. Berek as the\n lead investigator.\n\n\nTwo of the three participating U.S. centers have received all necessary\n regulatory approvals and are now actively recruiting patients. The\n third center is awaiting IRB approval. Additional information on the\n Company's clinical trial can be found listed in www.ClinicalTrials.gov.\n\n\n\"A systemic study of combinatorial immunization strategies such as the\n current trial with evidence based preliminary observations has the\n potential of revolutionizing cancer therapy and may lead to important\n commercial applications\" said Dr. Christopher Nicodemus, MD, FACP,\n Senior Advisor and Chairman of the Company's Clinical Advisory Board.\n\n\n\"We are pleased with the interest from the U.S. centers to participate\n in this important clinical trial. The additional centers will not only\n speed up patient enrollment for the study, but will raise the profile\n and awareness of Quest's lead immunotherapy product in the ovarian\n cancer community in North America\", said Dr. Madi R. Madiyalakan, PhD,\n Chief Executive Officer for Quest.\n\n\nAbout oregovomab\n\n\nQuest PharmaTech is developing oregovomab, a high affinity monoclonal\n antibody for the treatment of advanced ovarian cancer. Oregovomab\n targets the circulating t...